Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 30, Issue 13, p.1415-21 (2012)

Keywords:

2012, Adolescent, Age Factors, Alcohol Oxidoreductases, Anthracyclines, Antibiotics, Antineoplastic, Biotransformation, Cardiomyopathies, Case-Control Studies, Chi-Square Distribution, Child, Child, Preschool, Clinical Research Division, Dose-Response Relationship, Drug, Female, Genetic Predisposition to Disease, Homozygote, Humans, Infant, Infant, Newborn, June 2012, Logistic Models, Male, Neoplasms, Odds Ratio, Pharmacogenetics, PHENOTYPE, Polymorphism, Single Nucleotide, Risk Assessment, Risk Factors, Survivors, Time Factors, United States, Young Adult

Abstract:

Carbonyl reductases (CBRs) catalyze reduction of anthracyclines to cardiotoxic alcohol metabolites. Polymorphisms in CBR1 and CBR3 influence synthesis of these metabolites. We examined whether single nucleotide polymorphisms in CBR1 (CBR1 1096G>A) and/or CBR3 (CBR3 V244M) modified the dose-dependent risk of anthracycline-related cardiomyopathy in childhood cancer survivors.